JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the ...

Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against ...

The average one-year price target for Dyadic International (NasdaqCM:DYAI) has been revised to $7.14 / share. This is an increase of 40.00% from the prior estimate of $5.10 dated December 18, 2025.

Dyadic International said today it will sell its industrial technology business to DuPont’s Industrial Biosciences business for $75 million cash, in a deal that will reposition the seller exclusively ...

These events underscore Dyadic’s commitment to expanding its global footprint and advancing its mission to revolutionize biomanufacturing with its proprietary C1 and Dapibus™ technology platforms.

Improving patient outcomes, satisfaction and safety while using resources responsibly is foundational to the ever-changing world of kidney health care delivery. Leadership that succeeds clinically and ...

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy ...

Aiming for the courtroom equivalent of a pin, former collegiate wrestler Mark Emalfarb alleged blue-chip law firms robbed his biotech company of $185 million in vanished market capitalization and $700 ...

JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene ...